Dyne Therapeutics Inc [DYN] stock prices are up 4.37% to $14.56 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DYN shares have gain 16.48% over the last week, with a monthly amount glided 9.89%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Dyne Therapeutics Inc [NASDAQ: DYN] stock has seen the most recent analyst activity on August 25, 2025, when Raymond James upgraded its rating to a Strong Buy but kept the price target unchanged to $35 for it. Previously, Bernstein started tracking the stock with Mkt Perform rating on June 24, 2025, and set its price target to $13. Evercore ISI initiated its recommendation with a Outperform and recommended $46 as its price target on May 29, 2025. BMO Capital Markets started tracking with a Outperform rating for this stock on March 12, 2025, and assigned it a price target of $50. In a note dated March 07, 2025, Scotiabank initiated an Sector Outperform rating and provided a target price of $50 on this stock.
The stock price of Dyne Therapeutics Inc [DYN] has been fluctuating between $6.36 and $35.90 over the past year. Currently, Wall Street analysts expect the stock to reach $34.5 within the next 12 months. Dyne Therapeutics Inc [NASDAQ: DYN] shares were valued at $14.56 at the most recent close of the market. An investor can expect a potential return of 136.95% based on the average DYN price forecast.
Analyzing the DYN fundamentals
Gross Profit Margin for this corporation currently stands at -0.39% with Operating Profit Margin at -280.49%, Pretax Profit Margin comes in at -262.65%, and Net Profit Margin reading is -262.65%. To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -0.64 and Total Capital is -0.64. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.10 points at the first support level, and at 13.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.81, and for the 2nd resistance point, it is at 15.05.
Ratios To Look Out For
It’s worth pointing out that Dyne Therapeutics Inc [NASDAQ:DYN]’s Current Ratio is 16.83. Also, the Quick Ratio is 16.83, while the Cash Ratio stands at 11.7.
Transactions by insiders
Recent insider trading involved Cox John, CEO & President, that happened on Sep 05 ’25 when 2640.0 shares were sold. Chief Commercial Officer, Friedl-Naderer Johanna completed a deal on Sep 04 ’25 to sell 894.0 shares. Meanwhile, Chief Commercial Officer Friedl-Naderer Johanna sold 144.0 shares on Sep 05 ’25.
